SCHEMBL5369547

SCHEMBL5369547

CCOC(=O)N1CC=C(C(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.41
TSHR P16473 2/20 0.41
POLB P06746 3/20 0.41
MAPT P10636 2/20 0.41
ABL1 P00519 1/20 0.41
RIN1 Q13671 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.40
SLC6A15 Q9H2J7 1/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PABPC1 P11940 1/20 0.40
ATM Q13315 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
RXFP1 Q9HBX9 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19220891 0.88 MEN1 (0.40) TSHRSLC6A15ALDH1A1MEN1KMT2A
SCHEMBL3151019 0.88 GAA (0.40) GAATSHRPOLBMAPTABL1
SCHEMBL15837090 0.84 CYP2C9 (0.36) TSHRMAPTALDH1A1SMN1; SMN2CYP1A2
SCHEMBL19454517 0.83 GRM5 (0.44) SLC6A15
SCHEMBL19226371 0.82 HRH3 (0.41)
SCHEMBL12026425 0.81 NAMPT (0.47) GAAMAPTKDM4EALDH1A1MEN1
SCHEMBL7447957 0.80 MAPT (0.45) GAATSHRPOLBMAPTABL1
SCHEMBL12026412 0.80 PDK4 (0.51) MAPTALDH1A1SMN1; SMN2HTT
SCHEMBL146987 0.78 PDK4 (0.45)
SCHEMBL104852 0.78 QDPR (0.45) MAPTTDP1LMNACYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 US disclosed
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-03-02 US disclosed
EP-1773817-A1 SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2007-04-18 EP disclosed
WO-2006012374-A1 SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF GAA 4392/4885TSHR 2318/4885POLB 679/4885
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KRAS, HRAS, TP53 GAA 4392/4885TSHR 2240/4885POLB 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.